Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Open-label Study to Assess the Clinical Utility of Fluciclovine (18F) PET/CT in Patients With Prostate Cancer With Biochemical Recurrence After Radical Treatment

NCT02578940 is registered in ClinicalTrials.gov with Blue Earth Diagnostics as lead sponsor.

NCT NCT02578940
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02578940 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Open-label Study to Assess the Clinical Utility of Fluciclovine (18F) PET/CT in Patients With Prostate Cancer With Biochemical Recurrence After Radical Treatment
Lead sponsor
Blue Earth Diagnostics
Phase
Phase 3
Overall status
Completed
Start date
November 30, 2015
Completion date
June 22, 2018
Enrollment
104 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

cancer of the prostate